ATE258799T1 - Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort - Google Patents

Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort

Info

Publication number: ATE258799T1
Authority: AT; Austria
Prior art keywords: chlorite solution; stabilized chlorite; antigen; immune response; inhibit
Prior art date: 1997-10-06

Application number

AT98946681T

Other languages

English (en)

Inventor

Frederich W Kuhne

Michael Mcgrath

Boulevard

Edgar G Engleman

Original Assignee

Oxo Chemie Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-06

Filing date

1998-10-06

Publication date

2004-02-15

1998-10-06 Application filed by Oxo Chemie Ag filed Critical Oxo Chemie Ag

2004-02-15 Application granted granted Critical

2004-02-15 Publication of ATE258799T1 publication Critical patent/ATE258799T1/de

Links

229910001919 chlorite Inorganic materials 0.000 title abstract 4
229910052619 chlorite group Inorganic materials 0.000 title abstract 4
230000028993 immune response Effects 0.000 title abstract 3
QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 title 1
QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 abstract 3
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
208000030289 Lymphoproliferative disease Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT98946681T 1997-10-06 1998-10-06 Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort ATE258799T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6095397P	1997-10-06	1997-10-06
PCT/IB1998/001676 WO1999017787A2 (en)	1997-10-06	1998-10-06	Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response

Publications (1)

Publication Number	Publication Date
ATE258799T1 true ATE258799T1 (de)	2004-02-15

Family

ID=22032774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98946681T ATE258799T1 (de)	1997-10-06	1998-10-06	Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort

Country Status (12)

Country	Link
US (4)	US20050129784A1 (de)
EP (1)	EP1021196B1 (de)
JP (1)	JP4369615B2 (de)
CN (1)	CN1152691C (de)
AT (1)	ATE258799T1 (de)
AU (1)	AU754928B2 (de)
CA (1)	CA2306273A1 (de)
DE (1)	DE69821506T2 (de)
DK (1)	DK1021196T3 (de)
ES (1)	ES2217582T3 (de)
PT (1)	PT1021196E (de)
WO (1)	WO1999017787A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2382293A1 (en) *	1999-08-18	2001-02-22	Oxo Chemie Ag	Chemically-stabilized chlorite solutions for treating cancer and other diseases
AU2011205095B2 (en) *	2004-02-03	2014-07-03	The Regents Of The University Of California	Chlorite in the treatment of neurodegenerative disease
US7105183B2 (en) *	2004-02-03	2006-09-12	The Regents Of The University Of California	Chlorite in the treatment of neurodegenerative disease
AU2006331497B2 (en)	2005-12-22	2013-07-04	Neuraltus Pharmaceuticals, Inc.	Chlorite formulations, and methods of preparation and use thereof
US8252343B2 (en)	2007-06-01	2012-08-28	Nuvo Research Ag	Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
WO2011017030A2 (en) *	2009-08-06	2011-02-10	Neuraltus Pharmaceuticals, Inc.	Treatment of macrophage-related disorders
WO2011059926A2 (en)	2009-11-10	2011-05-19	Mayo Foundation For Medical Eduction And Research	Methods and materials for treating renal cell carcinoma
EP2793860A1 (de)	2011-12-22	2014-10-29	Nuvo Research GmbH	Liposomale chlorit- oder chloratzusammensetzungen
US20140356452A1 (en) *	2012-01-19	2014-12-04	Ibt Usa Inc.	Therapeutic Uses of Tetrachlorodecaoxygen (TCDO)
WO2014078272A1 (en)	2012-11-13	2014-05-22	Mayo Foundation For Medical Education And Research	Methods and materials for assessing immune system profiles
US10094835B2 (en)	2013-05-09	2018-10-09	Mayo Foundation For Medical Education And Research	Treating patients based on immune subtypes
US11813234B2 (en)	2015-08-20	2023-11-14	Oxo Translational Science Gmbh	Use of chlorite to treat red blood cell diseases and indications mediated thereby

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4574084A (en) *	1983-02-25	1986-03-04	Peter Berger	Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof
DE3515749A1 (de) *	1985-05-02	1986-11-06	Oxo Chemie GmbH, 6900 Heidelberg	Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden
DE3515745A1 (de) *	1985-05-02	1986-11-06	Oxo Chemie GmbH, 6900 Heidelberg	Waessrige chloritmatrix-loesung
US4851222A (en) *	1988-01-27	1989-07-25	Oxo Chemie Gmbh	Method of promoting regeneration of bone marrow
US4956184A (en) *	1988-05-06	1990-09-11	Alcide Corporation	Topical treatment of genital herpes lesions
DE4208828A1 (de) *	1992-03-19	1993-09-23	Oxo Chemie Gmbh	Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen
US5830511A (en) *	1992-06-25	1998-11-03	Bioxy Inc.	Therapeutic, production and immunostimulatory uses of biocidal compositions
US5877222A (en) *	1996-07-19	1999-03-02	The Regents Of The University Of California	Method for treating aids-associated dementia
US8252343B2 (en) *	2007-06-01	2012-08-28	Nuvo Research Ag	Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis

1998
- 1998-10-06 WO PCT/IB1998/001676 patent/WO1999017787A2/en not_active Ceased
- 1998-10-06 EP EP98946681A patent/EP1021196B1/de not_active Expired - Lifetime
- 1998-10-06 PT PT98946681T patent/PT1021196E/pt unknown
- 1998-10-06 ES ES98946681T patent/ES2217582T3/es not_active Expired - Lifetime
- 1998-10-06 AT AT98946681T patent/ATE258799T1/de active
- 1998-10-06 AU AU93642/98A patent/AU754928B2/en not_active Ceased
- 1998-10-06 DE DE69821506T patent/DE69821506T2/de not_active Expired - Lifetime
- 1998-10-06 CA CA002306273A patent/CA2306273A1/en not_active Abandoned
- 1998-10-06 CN CNB988118858A patent/CN1152691C/zh not_active Expired - Fee Related
- 1998-10-06 JP JP2000514658A patent/JP4369615B2/ja not_active Expired - Fee Related
- 1998-10-06 DK DK98946681T patent/DK1021196T3/da active
2004
- 2004-07-22 US US10/895,941 patent/US20050129784A1/en not_active Abandoned
2008
- 2008-06-04 US US12/132,761 patent/US20090004295A1/en not_active Abandoned
2010
- 2010-09-30 US US12/894,618 patent/US20110076344A1/en not_active Abandoned
2012
- 2012-02-06 US US13/366,595 patent/US20120141514A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2217582T3 (es)	2004-11-01
WO1999017787A2 (en)	1999-04-15
US20090004295A1 (en)	2009-01-01
AU754928B2 (en)	2002-11-28
US20120141514A1 (en)	2012-06-07
DE69821506D1 (de)	2004-03-11
WO1999017787A3 (en)	1999-06-17
DK1021196T3 (da)	2004-06-07
EP1021196A2 (de)	2000-07-26
EP1021196B1 (de)	2004-02-04
JP2001518512A (ja)	2001-10-16
AU9364298A (en)	1999-04-27
DE69821506T2 (de)	2004-12-16
JP4369615B2 (ja)	2009-11-25
CA2306273A1 (en)	1999-04-15
US20110076344A1 (en)	2011-03-31
CN1306433A (zh)	2001-08-01
CN1152691C (zh)	2004-06-09
US20050129784A1 (en)	2005-06-16
PT1021196E (pt)	2004-06-30

Legal Events

Date

Code

Title

Description

2004-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1021196

Country of ref document: EP

Publication	Publication Date	Title
Bloom et al.	1983	Selective primary health care: strategies for control of disease in the developing world. V. Leprosy
IL132468A0 (en)	2001-03-19	A kit for inducing immune response against a tumor or a disease caused by an infection agent
DE69821506D1 (de)	2004-03-11	Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
ES2112860T3 (es)	1998-04-16	Inmunoterapia adoptiva con interleukina-7.
DE69535328D1 (de)	2007-01-18	In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
LV12085A (lv)	1998-07-20	Dendritiskas sunas stimulejosais faktors
ATE231184T1 (de)	2003-02-15	Impfstoffe gegen die pest
SE9102808L (sv)	1993-03-27	Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
DK0633929T3 (da)	2004-06-28	Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
ATE64304T1 (de)	1991-06-15	Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.
CY1106400T1 (el)	2011-10-12	Συνθεση και μεθοδος ανοσοθepαπειας με καρκινικο αντιγονο
DE60234115D1 (de)	2009-12-03	Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
BR9811037A (pt)	2000-08-01	Utilização de ligantes mhc classe ii como coadjuvante para vacinação e de lag-3 no tratamento do câncer
ATE289823T1 (de)	2005-03-15	Erhöhung der migration oder proliferation von keratinocyten
ATE78403T1 (de)	1992-08-15	Impfstoff gegen mastitis.
HUP9800613A2 (hu)	1999-02-01	Humán Fas-antigén elleni humanizált antitest
DE69428272D1 (de)	2001-10-18	Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
DE69429521D1 (de)	2002-01-31	Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
SU629548A1 (ru)	1978-10-25	Способ моделировани амилоидоза
BR9808878A (pt)	2000-07-11	Imunização contra moléculas endógenas
DE69123252D1 (de)	1997-01-02	Kreuzreaktive immunisierung gegen influenza
Pazdernik et al.	1974	Carrier-and hapten-antibody producing cells, in vitro II. Effect of purine antimetabolites
RACIS	1987	PROSTAGLANDINS AS PHYSIOLOGICAL IMMUNOREGULATORS (LYMPHOCYTES, HELP, SUPPRESSION, ANTIBODY)
Burchiel	1977	Modulation of the in vitro humoral immune response by cyclic AMP
Val'konas	1989	The role of seasonal translocations of palearctic migrants in the spread of haemosporidians in birds